The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Vancomycin Resistance in Staphylococci
Open accessAbstract
SUMMARY: Vancomycin resistance has been reported in clinical isolates of both coagulase-negative staphylococci and Staphylococcus aureus . The emerging threat of widespread vancomycin resistance poses a serious public health concern given the fact that vancomycin has long been the preferred treatment of antibiotic-resistant gram-positive organisms. Though major efforts are now being focused on improving our understanding of vancomycin resistance, there is much that remains unknown at this time. This article reviews the major epidemiologic, microbiologic, and clinical characteristics of vancomycin resistance in both coagulase-negative staphylococci and S. aureus . The review begins with a discussion of issues common to both coagulase-negative staphylococci and S. aureus , such as definitions, laboratory detection of vancomycin resistance, and infection control issues related to vancomycin-resistant staphylococci. The rest of the article is then devoted to a discussion of issues unique to each organism, including epidemiology, risk factors for infection, mechanisms of resistance, and management options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984 · cited 3×
“Beta-lactam antibiotics have been used clinically in the treatment of two of the VISA cases, once in combination with an aminoglycoside (35) and once in combination with an aminoglycoside and vancomycin (24).”
BackgroundHiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Linezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
(1995) · American Journal of Infection Control · doi:10.1016/0196-6553(95)90104-3 · Cited by 709
Boyce, J. M., Potter-Bynoe, G., Chenevert, C., & King, T. C. (1997) · Infection Control and Hospital Epidemiology · doi:10.2307/30141488 · Cited by 673
Bugg, T. D. H., Wright, G. D., Dutka-Malen, S., Arthur, M., Courvalin, P., & Walsh, C. T. (1991) · Biochemistry · doi:10.1021/bi00107a007 · Cited by 650
Mulligan, M. E., Murray-Leisure, K. A., Ribner, B. S., Standiford, H. C., John, J. F., Korvick, J. A., Kauffman, C. A., & Yu, V. L. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90063-u · Cited by 641
Noble, W. C., Virani, Z., & Cree, R. G. A. (1992) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1992.tb05089.x · Cited by 627
Emergence of Vancomycin Resistance in Coagulase-Negative Staphylococci
Schwalbe, R. S., Stapleton, J. T., & Gilligan, P. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161507 · Cited by 584
Boyce, J. M., Opal, S. M., Chow, J. W., Zervos, M. J., Potter-Bynoe, G., Sherman, C. B., Romulo, R. L., Fortna, S., & Medeiros, A. A. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.5.1148-1153.1994 · Cited by 485
Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Tenover, F. C., Biddle, J. W., & Lancaster, M. V. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010237 · Cited by 391
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.4.1020-1027.1998 · Cited by 376
Hanaki, H. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.2.199 · Cited by 366
Rybak, M. J., Hershberger, E., Moldovan, T., & Grucz, R. G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1062-1066.2000 · Cited by 362
Tenover, F. C., Lancaster, M. V., Hill, B. C., Steward, C. D., Stocker, S. A., Hancock, G. A., O’Hara, C. M., McAllister, S. K., Clark, N. C., & Hiramatsu, K. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.2167-2167.1998 · Cited by 362
First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
Ploy, M., Grelaud, C., Martin, C., de Lumley, L., & Denis, F. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79166-2 · Cited by 331
Weinstein, R. A., & Fridkin, S. K. (2001) · Clinical Infectious Diseases · doi:10.1086/317542 · Cited by 304
Sieradzki, K., & Tomasz, A. (1997) · Journal of Bacteriology · doi:10.1128/jb.179.8.2557-2566.1997 · Cited by 274
Production of l-DOPA by Aspergillus terreus
Chattopadhyay, S., & Das, A. (1990) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1990.tb03888.x · Cited by 243
Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan, 1996
(1997) · American Journal of Infection Control · doi:10.1016/s0196-6553(97)90087-0 · Cited by 224
The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study
Ena, J. (1993) · JAMA · doi:10.1001/jama.269.5.598 · Cited by 203
Mode of action and in-vitro activity of vancomycin
Watanakunakorn, C. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/14.suppl_d.7 · Cited by 197
Climo, M. W., Patron, R. L., & Archer, G. L. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1747 · Cited by 189
SOME LABORATORY AND CLINICAL EXPERIENCES WITH A NEW ANTIBIOTIC, VANCOMYCIN
Geraci, J. E., Heilman, F. R., Nichols, D. R., Wellman, W. E., & Ross, G. T. (1956) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(26)01926-9 · Cited by 184
Rotun, S. S., McMath, V., Schoonmaker, D. J., Maupin, P. S., Tenover, F. C., Hill, B. C., & Ackman, D. M. (1999) · Emerging Infectious Diseases · doi:10.3201/eid0501.990118 · Cited by 167
Bacteremia Caused by Staphylococci with Inducible Vancomycin Heteroresistance
Wong, S. S. Y., Ho, P. L., Woo, P. C. Y., & Yuen, K. Y. (1999) · Clinical Infectious Diseases · doi:10.1086/520429 · Cited by 165
Glycopeptide Resistance in Coagulase-Negative Staphylococci
Biavasco, F., Vignaroli, C., & Varaldo, P. E. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960000299 · Cited by 160
Inactivated pbp4 in Highly Glycopeptide-resistant Laboratory Mutants of Staphylococcus aureus
Sieradzki, K., Pinho, M. G., & Tomasz, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.27.18942 · Cited by 153
Rybak, M. J., Cappelletty, D. M., Moldovan, T., Aeschlimann, J. R., & Kaatz, G. W. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.721 · Cited by 147
The threat of vancomycin resistance
Perl, T. M. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00354-4 · Cited by 134
Self-citationHenwood, C. J., Livermore, D. M., Johnson, A. P., James, D., Warner, M., & Gardiner, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.6.931 · Cited by 131
Moreira, B. M., Boyle‐Vavra, S., DeJonge, B. L. M., & Daum, R. S. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1788 · Cited by 131
Daum, R. S., Gupta, S., Sabbagh, R., & Milewski, W. M. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/166.5.1066 · Cited by 130
Sieradzki, K., & Tomasz, A. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.24.7566-7570.1999 · Cited by 125
Tenover, F. C., Mohammed, M. J., Stelling, J. M., O'Brien, T., & Williams, R. J. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.241-250.2001 · Cited by 112
Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999.
Khurshid, M., Chou, T. D., Carey, R. A., Larsen, R. A., Conover, C. S., & Bornstein, S. (2000) · MMWR Morbidity and Mortality Weekly Report · Cited by 109
de Neeling, A. J., van Leeuwen, W. J., Schouls, L. M., Schot, C. S., van Veen-Rutgers, A., Beunders, A. J. M., Buiting, A. G. M., Hol, C., Ligtvoet, E. E. J., Petit, P. L. C., et al. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/41.1.93 · Cited by 108
The Emergence of Decreased Susceptibility to Vancomycin in Staphylococcus epidermidis
Garrett, D. O., Jochimsen, E. M., Murfitt, K. C., Hill, B. C., McAllister, S. K., Nelson, P., Spera, R. V., Sall, R. K., Tenover, F. C., Johnston, J., et al. (1999) · Infection Control and Hospital Epidemiology · doi:10.1086/501605 · Cited by 106
Quinupristin-Dalfopristin Resistance among Gram-Positive Bacteria in Taiwan
Luh, K., Hsueh, P., Teng, L., Pan, H., Chen, Y.-C., Lu, J., Wu, J., & Ho, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3374-3380.2000 · Cited by 97
Inactivation of the Methicillin Resistance Gene mecA in Vancomycin-Resistant Staphylococcus aureus
Sieradzki, K., Wu, S. W., & Tomasz, A. (1999) · Microbial Drug Resistance · doi:10.1089/mdr.1999.5.253 · Cited by 84
Hubert, S. K., Mohammed, J. M., Fridkin, S. K., Gaynes, R. P., McGowan, J. E., & Tenover, F. C. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.11.3590-3593.1999 · Cited by 84
Vancomycin‐ResistantStaphylococcus aureus: Infection Control Considerations
Wenzel, R. P., & Edmond, M. B. (1998) · Clinical Infectious Diseases · doi:10.1086/514646 · Cited by 79
ANTISTAPHYLOCOCCAL (MSSA, MRSA, MSSE, MRSE) ANTIBIOTICS
Paradisi, F., Corti, G., & Messeri, D. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70302-3 · Cited by 73
Jorgensen, J. H., McElmeel, M. L., & Trippy, C. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.465 · Cited by 71
The specter of glycopeptide resistance: current trends and future considerations
Moellering, R. C. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00148-x · Cited by 54
Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.
(2000) · PubMed · Cited by 50
Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996.
(1997) · PubMed · Cited by 46
Vancomycin, a new antibiotic. II. In vitro antibacterial studies.
Jm, M., Rn, W., & Dw, Z. (2002) · PubMed · Cited by 42
Pina, P., Marliere, C., Vandenesch, F., Bedos, J. P., Étienne, J., & Allouch, P. (2000) · Clinical Infectious Diseases · doi:10.1086/317464 · Cited by 34
European glycopeptide susceptibility survey of Gram-positive bacteria for 1995
Felmingham, D., Brown, D. F., & Soussy, C. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00053-4 · Cited by 26
Dunne, W. M., Qureshi, H., Hassan, P., & Nafziger, D. A. (2001) · Clinical Infectious Diseases · doi:10.1086/320890 · Cited by 26
Vancomycin intermediate-resistant Staphylococcus aureus
Turco, T. F. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.18017 · Cited by 25
Laverdière, M., Weiss, K., Rivest, R., & Delorme, J. (1998) · Microbial Drug Resistance · doi:10.1089/mdr.1998.4.119 · Cited by 19
A multicentre study:Staphylococcus andEnterococcus susceptibility to antibiotics
Turano, A., Ravizzola, G., Peroni, L., Ceruti, T., Greco, L. M., Pitzus, E., Santini, G., Cresti, S., & Satta, G. (1994) · European Journal of Epidemiology · doi:10.1007/bf01719574 · Cited by 12
Cited by
Siegel, J. D., Rhinehart, E., Jackson, M., & Chiarello, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.10.007 · Cited by 3,456
Management of multidrug-resistant organisms in health care settings, 2006
Siegel, J. D., Rhinehart, E., Jackson, M., & Chiarello, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.10.006 · Cited by 1,283
Iwase, T., Uehara, Y., Shinji, H., Tajima, A., Seo, H., Takada, K., Agata, T., & Mizunoe, Y. (2010) · Nature · doi:10.1038/nature09074 · Cited by 991
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
The multifaceted roles of antibiotics and antibiotic resistance in nature
Sengupta, S., Chattopadhyay, M. K., & Grossart, H.-P. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00047 · Cited by 629
Metadata
- Authors
- Srinivasan, A., Dick, J. D., & Perl, T. M.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2002-07
- Volume
- 15
- Issue
- 3
- Pages
- 430-438
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2164493556
- Cited by
- 285
- References
- 58
- FWCI
- 9.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.